Numedicus uses therapeutic switching to identify secondary uses for existing drugs in practically all areas.
There are various types of collaborator that we work with:
- University departments of pharmacology (for example) with academic discoveries of new uses for existing drugs, seeking strategic assistance with commercialisation
- specialty pharma companies with existing products seeking indication expansion
- drug delivery companies seeking innovative new active products for incorporation into their devices or technology, with which new therapeutic uses often synergise
- mid-size pharmaceutical companies seeking new angles on their development portfolio or ideas for life cycle management, or a better understanding of the commercial potential for an in-licensing opportunity
Although therapeutic switching is not traditionally an area that large multinational companies might seek to work with Numedicus, there is increasing interest among such companies in the strategy.
Please use the menu at the left to navigate through this section.